ArticleInternational journal of bipolar disorders2026
SSRI versus SNRI initiation and incident bipolar disorder in tertiary psychiatric care: an active-comparator cohort study from the United Arab Emirates.
Article in International journal of bipolar disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhether antidepressant class influences the risk of subsequent bipolar disorder diagnosis remains clinically relevant, though direct active-comparator studies are scarce. We compared incident bipolar disorder risk between selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) initiators using tiered outcome definitions.
methodsWe conducted a retrospective cohort study from 2018 to 2025 using a 90-day landmark design at a tertiary psychiatric hospital in the United Arab Emirates. Adults aged 18–60 years initiating SSRIs or SNRIs for depressive disorders were followed for incident bipolar disorder. The primary outcome was anchored bipolar disorder, defined as two or more diagnoses at least 30 days apart plus new initiation of a mood stabiliser within 90 days of the first bipolar diagnosis. Secondary outcomes included confirmed bipolar disorder (two or more diagnoses) and any bipolar diagnosis. Cox proportional hazards models adjusted for age, sex, schizophrenia spectrum disorder, substance use disorder, and prior psychotropic use. Exploratory analyses examined individual antidepressants.
resultsAmong 1,095 antidepressant initiators (818 SSRI; 277 SNRI), 72 (6.6%) developed anchored bipolar disorder over 1,610.6 person-years. SSRI versus SNRI initiation was not associated with differential risk of anchored bipolar disorder (adjusted hazard ratio [aHR] 1.07, 95% CI 0.63–1.84, p = 0.80). Findings were consistent across secondary outcomes (confirmed: aHR 1.24, 95% CI 0.96–1.60; any diagnosis: aHR 1.13, 95% CI 0.92–1.38) and drug-level comparisons, including venlafaxine versus pooled SSRIs (aHR 1.27, 95% CI 0.62–2.60). Event rates varied seven-fold by outcome stringency (6.6% to 46.3%).
conclusionsAntidepressant class was not associated with incident bipolar disorder using stringent outcome definitions. The marked variation in event rates across outcome tiers suggests that higher conversion rates reported using less specific outcome definitions may partly reflect diagnostic revision and outcome misclassification, in addition to any underlying pharmacological or clinical factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.